CytoReason

Haifa, Israel Founded: 2016 • Age: 10 yrs
Immune system-based drugs are discovered via biological data analytics.

About CytoReason

CytoReason is a Healthcare company based in Haifa (Israel) founded in 2016. Immune system-based drugs are discovered via biological data analytics. CytoReason has raised $100 million across 3 funding rounds from investors including Thermo Fisher Scientific, Nvidia and OurCrowd. CytoReason offers products and services including Disease Model and Drug Portfolio Manager. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is CytoReason LTD.

Company details

CytoReason was founded in 2016 in Haifa, Israel, within the biotechnology sector. Immune system-based drugs are developed through a proprietary platform that integrates scientific and experimental data. The immune system is stimulated and analyzed using high-resolution patient data alongside scientific research to support drug discovery processes. Operations focus on biological data analytics for therapeutic advancements.

  • Headquarters Haifa, Israel
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website cytoreason.com
  • Social LinkedIn X
  • Legal Name Cytoreason Ltd
Key Metrics
  • Total Equity Funding
    $100M (USD)

    in 3 rounds

  • Latest Funding Round
    $80M (USD), Series C

    Jul 2024

  • Investors

Products & Services of CytoReason

CytoReason offers a comprehensive portfolio of products and services, including Disease Model and Drug Portfolio Manager.

Disease Model
AI Platform

AI tool for modeling diseases and comparing treatments.

Drug Portfolio Manager
Analytics Software

Platform to prioritize and compare drug programs across populations.

Funding Insights of CytoReason

CytoReason has successfully raised a total of $100M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $100M
  • Total Rounds 3
  • Last Round Series C β€” $80M
  • First Round $20M

    (Sep 2022)

  • Investors Count 5

All 3 funding rounds of CytoReason with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2024Debt – Conventional––
Jul 2024$80MSeries C–OurCrowd, NVIDIA
–
Sep 2022$20MSeries B––
Valuation history

5 investors in total: 5 institutional.

Investors in CytoReason

CytoReason has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, Nvidia and OurCrowd.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Pharmaceutical products for treating multiple diseases are provided.
1849pfizer.comNew York, United States
Secondary fund investments are emphasized by this Israeli commercial bank.
1921bankhapoalim.comTel Aviv, Israel
Network connecting investors to startups, venture capital funds, and alternatives
2013ourcrowd.comJerusalem, Israel
AI-powered graphical processing units and SoCs
1993nvidia.comSanta Clara, United States
Electron microscopy services and microanalysis instruments are provided.
1956thermofisher.comWaltham, United States
Premium access

Investor details for CytoReason

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of CytoReason

43 people are tracked at CytoReason (12 in leadership, 10 in board & advisors, 21 in team).

NameRoleGroup
Shai Shen-Orr
Co-Founder & Chief ScientistLeadership
David Harel
Chief Executive OfficerLeadership
eldad kadari
Vp, Business Development - Biopharma SolutionsLeadership
Nicole Van Poppel
Chief Business OfficerLeadership
Yehuda Chowers
Chief Medical OfficerLeadership
Noam Hadary
Director Of Model TeamLeadership
Liza Aizman
Senior Director Of Science Operations, Immune-oncologyLeadership
Yoav Aharoni
VP, R&DLeadership
Elina Starosvetsky
Co-Founder & VP, BiologyLeadership
Alexandra Sirota-Madi
VP Of Science OperationsLeadership
Tim O'Brien
Vice President Business Development And SalesLeadership
Ronen Schuster
Director Science OperationsLeadership
Jeremy Goldberg
DirectorBoard & advisors
Chris Sander
AdvisorBoard & advisors
John Tsang
AdvisorBoard & advisors
Michael Vincent
AdvisorBoard & advisors
Tom Bumol
AdvisorBoard & advisors
JC Gutiérrez-Ramos
AdvisorBoard & advisors
Fabian Theis
AdvisorBoard & advisors
Martin Wales
DirectorBoard & advisors

23 more people are available in the full profile.

Premium access

Complete people profiles for CytoReason

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of CytoReason

3 dated milestones of CytoReason across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded CytoReason is founded.
  2. Funding First funding round of $20.0M.
  3. Funding Latest funding round, Series C, of $80.0M.

Web traffic of CytoReason

The website of CytoReason (cytoreason.com) receives about 2.9K visits a month and ranks #2,644,026 among all websites worldwide, #3,609 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    2.9K

    ▼ 8.1% vs previous month

  • Unique visitors
    1.3K

    per month

  • Global rank
    #2,644,026

    among all websites

  • Category rank
    #3,609

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with CytoReason. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
crohnscolitisfoundation.org
100%
258.8K#196,222View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cytoreason

Premium access

Complete news archive for CytoReason

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CytoReason

CytoReason was founded in 2016 and raised its 1st funding round 6 years after it was founded.

CytoReason is headquartered in Haifa, Israel. It is registered at Haifa, Haifa District, Israel.

CytoReason is a funded company, having raised a total of $100M across 3 funding rounds to date. The company's 1st funding round was a Series B of $20M, raised on Sep 2022.

CytoReason was founded in 2016 in Haifa, Israel, within the biotechnology sector. Immune system-based drugs are developed through a proprietary platform that integrates scientific and experimental data. The immune system is stimulated and analyzed using high-resolution patient data alongside scientific research to support drug discovery processes. Operations focus on biological data analytics for therapeutic advancements.

CytoReason offers Disease Model and Drug Portfolio Manager.

CytoReason has 5 investors. Key investors include Thermo Fisher Scientific, Nvidia, OurCrowd, Pfizer, and Bank Hapoalim.

CytoReason operates through Cytoreason Ltd.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available